The incidence of myocardial hypertrophy was determined in a comparative study of tacrolimus-based immunosuppression with cyclosporine-based immunosuppression for prevention of acute graft-versus-host disease (GVHD) after unrelated donor bone marrow transplantation. Patients were evaluated for clinical and echocardiographic abnormalities at baseline (prior to pretreatment conditioning and the first dose of study drug) and at 5-8 weeks after transplant when stable levels of oral tacrolimus or cyclosporine had been achieved. Left ventricular geometry and performance were assessed by echocardiography which included 2-D measurements and one Doppler measurement. Derived echocardiographic measurements and left ventricular mass index (LVMI) were also determined. A cut-off of Ͻ111 g/m 2 was used for the upper limit of normal for LVMI. Forty-four patients were included in this study (21 tacrolimus and 23 cyclosporine), of which 31 were evaluable for a comparison with both baseline and posttransplant values. There was no significant difference in the changes from baseline for mean left ventricular mass (LVM) or LVM index (LVMI) between treatment groups. Also, within the tacrolimus group there were no significant changes for these variables from baseline to post-transplant evaluations. Within the cyclosporine group there were significant increases from baseline for mean LVM (P = 0.011) and LVMI (P = 0.007). The incidence of myocardial hypertrophy (change of LVMI from Ͻ111 g/m 2 baseline to Ͼ111 g/m 2 post transplant) was 20% in the tacrolimus group and 56% in the cyclosporine group (P = 0.109). Changes in the LVMI from baseline to post baseline were greater with cyclosporine than with tacrolimus therapy, and there was no evidence that tacrolimus causes myocardial hypertrophy or significant clinical changes in adult bone marrow transplant patients. The increase in LVMI after trans- 
Pharmacologic immunosuppression with regimens including cyclosporine is the most commonly used form of graftversus-host disease (GVHD) prophylaxis after hematopoietic stem cell transplantation (HSCT). 1 Tacrolimus is a more recently available agent that has been demonstrated to be more effective than cyclosporine both for the treatment and prevention of liver and kidney allograft rejection, as well as GVHD prevention. [2] [3] [4] In preclinical studies, GVHD was prevented after marrow transplantation in both rats and dogs with tacrolimus. Based on these results, studies of GVHD prevention after HSCT with regimens including tacrolimus were initiated. Despite being structurally different from cyclosporine, both agents have similar mechanisms of action through the inhibition of the calcineurin phosphatase activity. [5] [6] [7] They also have a similar spectrum of side-effects, with neurotoxicity, nephrotoxicity, hyperkalemia and hypertension being the most commonly reported in animal and clinical studies. 6 Less common sideeffects include thrombotic microangiopathy, lymphoproliferative disorders and cardiac toxicity. 8 Of the latter, arrhythmias and prolongation of the QT interval are the most frequently reported after solid organ transplantation. 9 In 1995, a single report described five cases of hypertrophic cardiomyopathy following solid organ transplantation procedures (liver and/or intestinal) in pediatric patients. 10 Two patients developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after immunosuppressive therapy was converted to cyclosporine. In the other three patients, the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug. This complication was first described in animals, and since this initial report of five patients, other patients developing myocardial hypertrophy during tacrolimus treatment have been described. [11] [12] [13] [14] However, there are no prospective randomized studies comparing echocardiographic parameters in tacrolimus-treated and cyclosporine-treated patients. We conducted a study to determine if there was any evidence for myocardial hypertrophy in adult patients (Ͼ12 years) receiving tacrolimus or cyclosporine therapy for prevention of GVHD following bone marrow transplantation.
Patients and methods

Patients
Between March 1995 and September 1996, 180 patients were enrolled in an IRB-approved randomized study comparing cyclosporine-based immunosuppression to tacrolimus-based immunosuppression after marrow transplantation from unrelated donors for the treatment of hematologic malignancies. 3 Patients 12 years of age or older were eligible for the study if they were scheduled to receive a bone marrow transplant from an unrelated donor for chronic myelogenous leukemia in chronic or accelerated phase, early acute leukemia or malignant lymphoma (first or second remission or in untreated first relapse), aplastic anemia (AA) or myelodysplastic syndrome (MDS). Fortyfour consecutive patients enrolled in the primary study also participated in a sub-study to compare the incidence of myocardial hypertrophy between these two treatment arms. Twenty-one patients received tacrolimus and 23 received cyclosporine. All 44 patients received a bone marrow transplant and at least one dose of study drug, and underwent at least one echocardiographic evaluation. Five patients in the tacrolimus group were not included in the myocardial hypertrophy analysis. All five patients did not have posttransplant 2-D echocardiographic measurements because of their clinical condition. Eight patients in the cyclosporine group were not included in the incidence analysis; six patients did not have post-transplant 2-D echocardiographic evaluations, and the other two patients did not have baseline 2-D echocardiographic measurements for clinical reasons. None of the patients had clinical changes in their cardiac status to exclude them from the 2-D echocardiographic assessment. Patient demographic characteristics are listed in Table 1 .
All patients received preparative regimens that included either cyclophosphamide plus total body irradiation (TBI) or cyclophosphamide plus busulfan. On the day prior to marrow transplantation (day −1), patients were given either tacrolimus (0.03 mg/kg/day) or cyclosporine (3 mg/kg/day) as a continuous intravenous infusion. Both intravenous and oral doses of each study group were calculated based on lean body weights. All patients were scheduled to continue immunosuppression with these drugs as randomized for 6 months after transplant. Patients were converted from the i.v. to the oral formulation of tacrolimus and cyclosporine when the last i.v. dose given in two divided doses per day based on the last i.v. dose was tolerated four times. Dosage adjustments were permitted during the course of the study. All patients received standard-dose, short-course methotrexate therapy in addition to the study drug. Methotrexate Patient population: all patients who received bone marrow transplants and at least one dose of study drug, and who underwent echocardiographic evaluation. Significant difference between treatment groups for gender, P = 0.035, chi-squared test. NS = not significant, P Ͼ 0.20. Cy = cyclophosphamide; TBI = total body irradiation; Bu = busulfan; MDS = myelodysplastic syndrome; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myeloid leukemia.
was administered as an i.v. bolus (15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6 and 11). Measurements of whole blood tacrolimus were by IMx assay and cyclosporine levels were by monoclonal or polyclonal antibody assay or HPLC, respectively. 15, 16 The target blood concentration ranges were: tacrolimus 10-30 ng/ml 17, 18 and cyclosporine 300-900 ng/ml (as measured by polyclonal immunoassay). Dose reductions of tacrolimus and cyclosporine were recommended for increases in serum creatinine of Ͼ1.5 times of baseline or other serious toxicities associated with these agents.
Echocardiography
In this study, left ventricular geometry (eg wall thickness, diastolic and systolic dimensions, septal size) and performance (eg fractional shortening) were assessed. Measures of left ventricular geometry and performance were as follows: (1) A cut-off of 111 g/m 2 was used for the upper limit of normal for LVMI based on evaluations performed in a normal population. 19 Measurements were made at baseline (prior to pretransplant conditioning and before the first dose of study drug) and at 5-8 weeks after transplant. Observations were recorded before 5 weeks after transplant if clinically relevant. The 2-D measurements of left ventricular (LV) and diastolic dimension, systolic dimension, septum, posterior wall thickness, and left atrial size were made in real-time during examination with electronic calipers. The left ventricular measurements were made on a plane perpendicular to the long axis of the heart at the level of the chordae tendinae between the tips of the mitral leaflets and the tips of the papillary muscles. These measurements were made in long axis views. The left atrial measurement was also made in long axis view, as was the anterior-posterior dimension just above the aortic leaflets. M-mode dimensions were included in the echocardiography report and 2-D measurements were calculated.
Statistical analysis
A modified intent-to-treat analysis was used. The primary objective in this study was to determine the incidence of left ventricular (myocardial) hypertrophy based on measures of left ventricular geometry and performance.
After the initiation of this sub-study, all patients at FHCRC who received a bone marrow transplant and at least one dose of study drug, and who had echocardiography measurements were included in the echocardiographic analyses. Four types of statistical methods were conducted in the selected parameters in this study. Comparisons between treatment groups were made by chi-square test for categorical variables and t-test for continuous variables. The change from baseline in echocardiographic measurements was tested by paired t-test for continuous variables. For variables in the contingency table, Fisher's exact test was used for comparison between treatment groups.
Results
Patient characteristics and demographics
A total of 44 patients were enrolled in this study (21 tacrolimus, 23 cyclosporine). Patient demographics and baseline characteristics are presented in Table 1 . There was a statistically significant difference between treatment groups for patient gender, with more female than male patients in the tacrolimus group (67% vs 33%) and more male than female patients in the cyclosporine group (65% vs 35%) (P = 0.035, chi-square test). There were no significant differences between treatment groups for other demographic or baseline variables.
Cardiac abnormalities identified at baseline
At baseline there were two patients in the tacrolimus group with evidence of cardiac abnormalities by 2-D echocardiography. Both patients had mild mitral valve prolapse by 2-D echocardiographic evaluation at baseline but remained Bone Marrow Transplantation clinically asymptomatic during the study and without 2-D echocardiographic changes post transplant.
Four patients in the cyclosporine group had evidence of cardiac abnormalities by 2-D echocardiography at baseline. Three patients had aortic or mitral valve regurgitation. One of these patients was clinically symptomatic with left atrial and ventricular enlargement. LVMI at baseline was increased in two of these patients which persisted in one after transplant. The second patient died from a septic event after transplant without echocardiographic evaluation. A fifth patient in this group had normal 2-D echocardiograph and LVMI at baseline but had asymptomatic atrial fibrillation.
2-D echocardiography measurements
A summary of the measurements before and after transplant is presented in Table 2 . There were no significant differences between treatment groups for any changes in clinical or echocardiographic measurements after transplantation. Within the tacrolimus group, there were significant increases after transplant of the mean LVPW and IVS (P = 0.044 and P Ͻ 0.001, respectively, paired t-tests) and a significant decrease from baseline for mean LVED (P = 0.014, paired t-test). Within the cyclosporine group, there were significant increases after transplant in the mean diastolic blood pressure, LVPW and IVS (P = 0.020, P Ͻ 0.001, and P Ͻ 0.001, respectively, paired t-test). The baseline and post-transplant fractional shortening/FS values were within the normal range, and there was no suggestion of differences between the groups. No patient in either group developed subvalvular left ventricular outflow obstruction as assessed by Doppler.
Derived echocardiography parameters
There were no significant differences in the changes of the mean LVM (P = 0.2066) or LVMI (P = 0.1509) after transplant between treatment groups (Table 2 ). In addition, there were no significant changes after transplant within the tacrolimus group for these variables (Figure 1 ). Within the cyclosporine group, however, there were significant increases from baseline of the mean LVM and LVMI (P = 0.011 and P = 0.007, respectively, paired t-test). Table 3 describes the number of patients by left ventricular mass index category. Sixteen patients in the tacrolimus group and 15 in the cyclosporine group were evaluable for LVMI both at baseline and after transplant. Ten patients in the tacrolimus group and nine in the cyclosporine group had a baseline LVMI of Ͻ111 g/m 2 . Of these patients, two in the tacrolimus group and five in the cyclosporine group developed an LVMI of Ͼ111 g/m 2 . Therefore, the incidence of myocardial hypertrophy was 20% (2/10) in the tacrolimus group and 56% (5/9) in the cyclosporine group (P = 0.109).
Patients with increased left ventricular mass index (LVMI) assessments
Six tacrolimus-treated patients had LVMI Ͼ111g/m 2 at baseline. The LVMI value decreased to within normal lim- Figure 1 Changes of LVMI from baseline (B) to post transplant (PB) for both study groups. There were no significant differences between treatment groups for changes on LVMI (P = 0.15).
Table 3
Number of patients by left ventricular mass index category There were no significant differences in the incidence of myocardial hypertrophy between treatment groups (P = 0.170, Fisher's exact test). None of the seven patients with changes in LVMI from normal (Ͻ111 g/m 2 ) at baseline to high (Ͼ111 g/m 2 ) post transplant developed outflow obstruction. Outflow obstruction is best determined by measurement of left ventricular outflow tract velocity (LVOT) and these measurements did not change from baseline. Table 4 describes the characteristics of patients who developed hypertrophic cardiomyopathy.
Discussion
Cardiac toxicity has been reported as a complication after BMT. Despite numerous reports, the actual risk of developing this complication is not clearly defined. 20 There are several factors that can contribute to the development of cardiac disease (ie previous chemotherapy, conditioning regimen, fluid replacement, sepsis, medications, development of VOD). All of these can cause hemodynamic changes that can alter the anatomy and physiology of the heart. However, not all of these changes are clinically detectable, and only with the routine use of special diagnostic tests such as echocardiography, can they be determined at a subclinical level. This may explain why the incidence of cardiac abnormalities may be underestimated in some reports. Tacrolimus, approved initially for the prevention Patient population: all patients who received bone marrow transplant and at least one dose of study drug and who underwent baseline and post-baseline evaluations for myocardial hypertrophy.
and treatment of graft rejection after solid organ transplant, has gained interest in the setting of marrow transplantation for the prevention and treatment of acute GVHD. 3, [21] [22] [23] [24] It has a mechanism of action and a spectrum of side-effects similar to those of cyclosporine. 8 Concern about cardiac toxicities has resulted from a series of reports associating tacrolimus with the development of arrhythmias, prolongation of the QT interval and more recently the development of hypertrophic cardiomyopathy. 10, 13 Myocardial hypertrophy was reported in bone marrow transplant recipients prior to the availability of tacrolimus and has subsequently been reported in tacrolimus-treated patients. 8, [11] [12] [13] [14] Since most of these publications have not been randomized, our major objective was to study the incidence of hypertrophic cardiomyopathy after HSCT, based on mean increases in LVMI above the cut-off point of 111 g/m 2 in a subpopulation of patients who were randomized to receive either tacrolimus or cyclosporine for prevention of GVHD.
Atkison et al 10 described five consecutive pediatric transplant recipients (three small bowel with or without liver and two liver transplants) who developed cardiac hypertrophy after tacrolimus treatment. Two of the patients developed congestive heart failure and hypertrophic obstructive cardiomyopathy that resolved after changing to cyclosporine, and three recipients developed cardiomyopathy that regressed or improved with a lower dose of tacrolimus or after stopping the drug. Diagnoses were made by post-operative 2-D echocardiography. The author speculated that cardiac hypertrophy may be more pronounced with the higher doses of tacrolimus used in small bowel transplant recipients, although no clear dose relationship
Bone Marrow Transplantation was seen. The development of hypertrophic cardiomyopathy in one of the study patients provided evidence that tacrolimus could be the primary cause of this event. In this case, hypertrophic cardiomyopathy regressed after tacrolimus was discontinued and recurred within 2 months of restarting the drug. The pathophysiology of the observed cardiac enlargement and/or cardiomyopathy is unclear. It appears to be dose-related in that it has been more frequently reported in patients undergoing small bowel transplantation in whom high blood levels are required for efficacy. In such cases liver function and nephrotoxicity with fluid retention can result in cardiovascular stress leading to cardiac hypertrophy. Fluid overload and the use of corticosteroids would also be expected to produce a similar effect. All of the patients in the Atkison study were also receiving prednisone. Corticosteroids have been associated with the development of hypertrophic cardiomyopathy in the pediatric population. 25 One of the two patients in the tacrolimus group and two of the five in the cyclosporine group who developed hypertrophic cardiomyopathy were on steroids at the time of post-transplant evaluation. Of the patients who did not develop hypertrophic cardiomyopathy (cyclosporine, n = 4; tacrolimus, n = 8), none were on steroids at the time of post-transplant evaluation.
Another study in adult patients performed by Dollinger et al 26 reported that four of 12 patients developed cardiac abnormalities (left ventricular hypertrophy) after undergoing liver transplantation with tacrolimus. All of the patients had tacrolimus levels targeted between 10 and 20 ng/ml. Patients were followed pre-and post transplant with 2-D echocardiography assessment, and it was concluded that although 2-D echocardiography abnormalities are common after orthotopic liver transplantation, there was no obvious relation to the use of tacrolimus.
Hypertrophic cardiomyopathy has also been reported as a complication of cyclosporine therapy in transplant patients. Cyclosporine-induced hypertrophic cardiomyopathy is frequently associated with systemic hypertension and it has been suggested that cyclosporine has a direct vasoconstrictor effect not only in the renal, but also in the systemic circulation. 27, 28 Postulated mechanisms for this include changes in prostaglandin synthesis and activation of the renin-angiotensin and sympathetic nervous system. Typically, this has features of concentric hypertrophic cardiomyopathy (CHC) with lowered ejection fraction leading to left ventricular failure. The reported cardiomyopathy associated with the use of tacrolimus in transplant patients appears to have many characteristics in common with that observed in patients treated with other immunosuppressive drugs. Hypertrophy, concentric or asymmetric, is a common finding, as is the absence of cell distortion on microscopic examination. As with corticosteroids and cyclosporine, pediatric transplant recipients appear to be particularly susceptible. This may be a consequence of the higher doses usually required for efficacy in pediatric patients. 29, 30 The observation of microscopic intramyocardial calcification has led to the postulation of a potential mechanism involving displacement of FKBP-12 (the soluble receptor for FK-506) from the calcium release channel/ryanodine receptor of skeletal and cardiac muscle. This mechanism could potentially lead to increased outflow of calcium from the sarcoplasm and interfere with excitation-contraction coupling. In our study we found a total of seven patients (two in the tacrolimus group and five in the cyclosporine group) that met the definition of cardiac hypertrophy based on elevated LVMI (Ͼ111 g/m 2 ) measurements post transplant. Table 4 describes the characteristics of these patients. From Table 4 it can be seen that there were some confounding or competing factors that can explain the change in LVMI observed in both populations at study. All seven patients in our study had hypertension (defined by a systolic Ͼ140 and or diastolic of Ͼ90 mm Hg).
In summary, it was demonstrated in a randomized study that the incidence of hypertrophic cardiomyopathy was lower in the tacrolimus group compared to those patients receiving cyclosporine. Patient age, previous cardiac disease, conditioning regimen, treatment with steroids, and dosing of immunosuppressive agents may all have a role in predisposing patients to develop hypertrophic cardiomyopathy. No significant cardiac disease occurred in either group based on the changes observed in echocardiography. Cardiomyopathy associated with tacrolimus in marrow transplantation patients, if it exists, may be idiosyncratic and may be missed in a study with a small number of patients. The increase in LVMI after transplant was greater in the cyclosporine group than in the tacrolimus group but was not associated with any significant clinical event.
